NMRA INVESTOR NOTICE: Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action lawsuit due to alleged misleading information in its IPO registration statement, which has resulted in significant financial losses for investors [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit, titled Chang v. Neumora Therapeutics, Inc., allows purchasers of Neumora's common stock from its IPO on September 15, 2023, to seek lead plaintiff status until April 7, 2025 [1][5]. - The lawsuit alleges that Neumora and its executives misled investors regarding the efficacy of its flagship therapeutic candidate, Navacaprant, particularly in relation to its Phase Two and Phase Three clinical trials [2][3]. Group 2: Financial Impact - Neumora's IPO involved the sale of 14.7 million shares at a price of $17.00 per share [2]. - Following the announcement of the KOASTAL-1 study results on January 2, 2025, which failed to show significant improvement in depression treatment, Neumora's stock price plummeted to $1.91 per share, marking an 88.7% decline from the IPO price [4]. Group 3: Allegations Against Neumora - The lawsuit claims that Neumora altered the Phase Two Trial criteria to include a broader patient population to support its claims of Navacaprant's effectiveness [3]. - It is alleged that the Phase Two Trials lacked sufficient data, particularly regarding patient demographics, which undermined the reliability of the study results [3]. Group 4: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing investors in this class action lawsuit, highlighting its track record in securing monetary relief for investors in securities fraud cases [6].